# Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

> **NCT07502287** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 36 (estimated)

## Conditions studied

- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- High-Risk Neuroblastoma
- Ganglioneuroblastoma

## Interventions

- **BIOLOGICAL:** EB-DTNB-NK
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07502287
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-14
- **Final completion:** 2028-06-17
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502287, "Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07502287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*